As evidenced by CHIP-PCR, we found that the TF binding site (TFBS) of five TFs had binding events to BRD4 after it was cultured with or without CM of ovarian cancer cells (Figure 4B), among which PRDM1 and MAF had increasing binding events after CM treatment (Figure 4C). This evidence concerns the gene BRD4 and ovarian carcinoma.